Progress on clinical applications of chlormadinone acetate

Chlormadinone acetate (CMA), a 17a-Hydroxyprogesterone derivative, was primarily used for oral contraception in combination with ethinylestradiol (EE) in various regions, including Europe and Latin America. Besides its contraceptive role, CMA provided non-contraceptive benefits for conditions such as dysmenorrhea, androgen excess-related diseases (including acne, seborrheic dermatitis, female hair loss, hirsutism, and benign prostatic hyperplasia), and alleviated premenstrual or menstrual discomfort. The article reviewed these clinical applications to support its further and reasonable use in clinical treatments.